Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Revenues	$ 119,567	$ 113,671	$ 76,190
Cost of revenues	59,229	46,899	26,353
Gross profit	60,338	66,772	49,837
Operating expenses:
Research and development, net	21,659	15,919	9,583
Clinical operations	6,591	9,365	4,332
Sales and marketing	72,842	100,641	47,705
General and administrative	36,270	34,770	10,199
Impairment of goodwill	6,134	0	0
Total operating expenses	143,496	160,695	71,819
Operating loss	(83,158)	(93,923)	(21,982)
Financial (income) expense, net	(3,740)	(31,228)	364
Loss before taxes on income	(79,418)	(62,695)	(22,346)
Taxes on income	254	47	24
Net loss	$ (79,672)	$ (62,742)	$ (22,370)
Net loss per share:
Earnings Per Share, Basic	$ (0.51)	$ (0.72)	$ (1.67)
Earnings Per Share, Diluted	$ (0.51)	$ (0.72)	$ (1.67)
Weighted average number of common shares used in computing basic net loss per share	156,885,256	86,775,948	13,359,350
Weighted average number of common shares used in computing diluted net loss per share	156,885,256	86,775,948	13,359,350